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ABSTRACT
ObjectiveaaTo investigate whether baseline olfactory dysfunction in Parkinson’s disease (PD) patients is associated with base-
line and longitudinal motor and cognitive function.
MethodsaaWe recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cul-
tural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) 
nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as 
normosmia (CCSIT score ≥ 9), hyposmia (CCSIT score 5–8), and anosmia (CCSIT score ≤ 4). During the follow-up period, we 
investigated changes in the levodopa-equivalent dose (LED) and the occurrence of wearing-off, levodopa-induced dyskinesia, 
and dementia.
ResultsaaAmong the PD patients, 80.7% were hyposmic at the time of diagnosis, and 26.1% were anosmic. Baseline olfactory dys-
function was not associated with either initial parkinsonian motor symptoms or with the longitudinal LED increment and mo-
tor complications. Meanwhile, the anosmic group had lower baseline scores on the Korea version of the Boston Naming Test and 
Stroop color reading test than the normosmic and hyposmic groups. The anosmic group exhibited a higher rate of conversion to 
dementia than the normosmic [adjusted hazard ratio (HR) 3.99, 95% confidence interval (CI) 1.08–14.72] and hyposmic (adjust-
ed HR 2.48, 95% CI 1.15–5.32) PD groups, regardless of baseline motor deficits and cognitive status.
ConclusionaaBaseline olfactory dysfunction was not associated with motor deficits and complications, but it was associated with 
cognitive dysfunction and prognosis, suggesting that severe olfactory impairment may reflect early cortical involvement, proba-
bly in the frontotemporal region, and rapid spreading of Lewy body pathology.
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Olfactory dysfunction is an important prodromal non-motor 
symptom of Parkinson’s disease (PD).1 It often predates the diag-
nosis of PD by at least four years,2 and 70–80% of patients with 
PD already have decreased olfaction at the time of diagnosis.3 
Braak et al.4 found that the anterior olfactory nucleus is one of 
the earliest sites where Lewy bodies are observed. Moreover, ol-
factory deficits significantly increase the rate of phenoconver-
sion from rapid eye movement sleep behavior disorder (RBD) 
to PD.5 Accordingly, olfactory dysfunction has been a potential 
biomarker for the early and differential diagnosis of PD.
Many studies have investigated the association between olfac-
tory impairment and various motor and non-motor symptoms. 
It is still unclear whether olfactory dysfunction is associated with 
parkinsonian motor deficits. The Parkinson’s Progression Mark-
ers Initiative, a study that recruited PD patients with a disease 
duration of less than two years, reported that olfactory impair-
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ment was not associated with the Unified Parkinson’s Disease 
Rating Scale (UPDRS) motor score, disease duration, or dopa-
mine transporter (DAT) deficit.6 Meanwhile, a pathologic study 
revealed that synucleinopathy density scores in the olfactory 
bulb are correlated with UPDRS motor scores. The olfactory 
function score was correlated with the UPDRS motor score and 
putaminal DAT binding.7 Regarding cognition, olfactory dys-
function has been consistently reported to be associated with 
cognitive impairment and conversion to dementia in PD.3,6,8-10 
In a positron emission tomography (PET) study, olfactory iden-
tification impairment was correlated with DAT activity in the 
caudate nuclei.11
In this study, we investigated the association of olfactory dys-
function with baseline motor and cognitive dysfunction, DAT 
activity, levodopa-equivalent dose (LED) increments, and the 
occurrence of motor and cognitive complications in drug-naïve 
PD patients during a follow-up period of 3–10 years. We hypoth-
esized that olfactory dysfunction may be differentially associat-
ed with motor and cognitive deficits and their prognoses.
MATERIALS & METHODS
Study participants
In this retrospective cohort study, we consecutively recruited 
228 drug-naïve patients with PD who visited the movement dis-
orders outpatient clinic at Severance Hospital, Yonsei University 
Health System, from June 2009 to March 2016; all included pa-
tients has been followed for at least three years and up to 10 years. 
All subjects had undergone neurological examination, UPDRS, 
Cross-Cultural Smell Identification Test (CCSIT), neuropsy-
chological test, brain magnetic resonance imaging (MRI), and 
N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) 
nortropane (18F-FP-CIT) PET within six months. The diagnosis 
of PD was based on the clinical diagnostic criteria of the United 
Kingdom PD Society Brain Bank. All patients with PD showed 
decreased DAT uptake in the posterior putamen and responded 
to dopaminergic medication. RBD was assessed with the RBD 
Screening Questionnaire. The LED was calculated according to 
a previously described method.12 We excluded patients with se-
vere white matter hyperintensities; multiple lacunes in the bas-
al ganglia or hydrocephalus on MRI; other neurologic, psychi-
atric, or metabolic illnesses; dementia at baseline evaluation; 
atypical parkinsonism such as multiple system atrophy, corti-
cobasal degeneration, or progressive supranuclear palsy; or any 
conditions affecting olfactory function, including history of na-
sal surgery, chronic sinonasal disease, recent upper respiratory 
tract infections, or major head trauma.
This study was approved by the Institutional Review Board 
of Yonsei University Severance Hospital (IRB No. 4-2014-0637). 
Given the retrospective nature of the present study, written in-
formed consent was waived.
Assessment of olfactory function and grouping 
according to olfactory function
Olfactory function was assessed with the CCSIT, which con-
sists of 12 odors.13 Participants were required to scratch the panel, 
sniff the sample, and select from one of four possible answers. 
Their scores were calculated as the sum of correct responses. 
Based on previous studies, normosmia was diagnosed when 
the score ranged from 9 to 12, hyposmia was diagnosed when 
the score ranged from 5 to 8, and anosmia was diagnosed when 
the score ranged from 0 to 4.14
PET image acquisition
18F-FP-CIT PET scans were obtained using a Discovery 600 
system (General Electric Healthcare, Milwaukee, MI, USA). A 
dose of 185 MBq (5 mCi) of 18F-FP-CIT was injected intrave-
nously during the procedure. Ninety minutes after the injection, 
images were acquired during a 20-minute session, followed by 
a CT scan for attenuation correction. The spiral CT scan was 
performed with a 0.8 s/rotation at 120 kVp, 10 mA, 3.75 mm 
slice thickness, 0.625 mm collimation and 9.375 mm table feed 
per rotation. Images were reconstructed using the ordered sub-
set expectation maximization algorithm with ƒ iterations and 
32 subsets. A Gaussian filter with a full-width at half-maximum 
of 4 mm was applied to each reconstructed PET image, which 
was made up of a 256 × 256 matrix with 0.98 mm pixel and 
0.98 mm slice thickness.
Quantitation of the 18F FP-CIT PET-CT images
We analyzed the 18F-FP-CIT PET images according to the 
method described in a previous study.15 Image processing was 
performed using Statistical Parametric Mapping 8 (Wellcome 
Department of Imaging Neuroscience, Institute of Neurology, 
University College London, London, UK) with MATLAB R2013a 
for Windows (Math Works, Natick, MA, USA). Quantitative anal-
yses were based on the volumes of interest (VOIs), which were 
defined based on a template in standard space. All reconstructed 
PET images were spatially normalized to Talairach space by us-
ing a standard 18F-FP-CIT PET template, which was made in-
house, as described previously.16 Four VOIs of the bilateral cau-
date nuclei and putamen and one occipital VOI were drawn on 
a coregistered spatially normalized single T1 MRI and 18F-FP-
CIT PET template image on MRIcro version 1.37 (Chris Ror-
den, Columbia, SC, USA). These VOIs were adjusted by minor 
translation using our in-house editing software, ANIQUE (De-
partment of Nuclear Medicine, Asan Medical Center, University 
of Ulsan College of Medicine, Seoul, Korea). The level of DAT 
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activity in each VOI was calculated in terms of the specific to 
non-specific binding ratio as follows: (mean standardized up-
take of the striatal subregional VOI-mean standardized uptake 
of the occipital VOI)/mean standardized uptake of the occipi-
tal VOI. For non-specific binding, the mean standardized up-
take value was calculated by drawing two occipital VOIs, one 
on each side.
Clinical parameters and assessment of motor function
At baseline, parkinsonian motor symptoms were assessed dur-
ing a drug-naïve state at the time of 18F-FP-CIT PET acquisition 
using the UPDRS motor (UPDRS-III) subscales. Tremor and 
non-tremor scores were calculated in each patient according to 
a previously described method, and patients were classified into 
three clinical subtypes: tremor-dominant, akinetic-rigid, and 
mixed.17 DAT activity in the putamen was used to evaluate stri-
atal function in relation to parkinsonian motor function. 
We investigated longitudinal changes in the dose of dopami-
nergic medication using the LED during the first three years of 
follow-up, which can indirectly reflect the progression of parkin-
sonian motor symptoms. We also assessed the occurrence of mo-
tor complications, including wearing-off (WO) and levodopa-
induced dyskinesia (LID), during the follow-up period. Patients 
with PD visited the outpatient clinic every three to six months, 
and two movement disorders experts (Y.H.S. and P.H.L.) care-
fully examined them for the presence of motor complications 
based on the patient history provided by the patients and their 
caregivers or by performing direct neurological examination at 
every visit. We considered the date on which the PD patients or 
their caregivers reported the occurrence of motor complications 
or the date on which motor complications were first observed in 
the clinic as the date of the occurrence of motor complications.
Clinical parameters and assessment of cognitive 
function
At baseline, all participants underwent a standardized neuro-
psychological battery called the Seoul Neuropsychological Screen-
ing Battery,18 which is composed of the following scorable tests: 
digit span (forward and backward), repetition, the Korean ver-
sion of the Boston Naming Test (K-BNT), the 6-point pentagon 
drawing test, the Rey-Osterrieth Complex Figure Test (copying, 
immediate and 20-min delayed recall, and recognition), the 
Seoul Verbal Learning Test (SVLT; immediate recall, 20-min 
delayed recall, and recognition), contrasting programming and 
the go/no-go test, the clock drawing test, the phonemic and se-
mantic Controlled Oral Word Association Test, the Stroop Test 
(word and color reading), the Korean version of the Mini-Men-
tal State Examination (K-MMSE), and the Clinical Dementia 
Rating. Each score was converted into a standardized score (z-
score) based on age- and education-specific norms. Patients were 
diagnosed with PD with intact cognition when impairments 
were observed in less than two items on the detailed neuropsy-
chological tests. In accordance with the Movement Disorder So-
ciety Task Force guidelines, a diagnosis of PD with mild cogni-
tive impairment (MCI) was made when there was no evidence 
of abnormal activities in daily living (ADLs). DAT activity in the 
caudate was used to assess striatal function in relation to cog-
nitive function.
PD patients were followed-up for more than three years, and 
they performed neuropsychological tests or the K-MMSE every 
two to three years or when they or their caregivers complained 
of cognitive decline in their daily living activities. Patients were 
diagnosed with PD with dementia if they fulfilled the clinical 
criteria for probable PD with dementia based on the Movement 
Disorder Society Task Force guideline (both level I and II test-
ing) with evidence of abnormal ADLs. Impairment of cogni-
tive decline in ADLs was assessed both clinically and with the 
ADL scale.
Statistical analyses
The baseline demographic characteristics of the study partici-
pants were analyzed using the independent t-test or Pearson χ2-
test as appropriate. To compare baseline motor and cognitive 
parameters, we performed analysis of covariance (ANCOVA) 
using age, sex, and the interval from PD onset to CCSIT evalu-
ation as covariates for continuous variables, and we performed 
the Pearson χ2-test for categorical variables. Partial correlation 
analysis was performed to investigate the correlation between 
the CCSIT score and neuropsychological performance. Correc-
tions for multiple analyses across 15 neuropsychological items 
were performed using the false discovery rate (FDR) method in 
the ANCOVA and partial correlation analyses. A linear mixed 
model was used to examine the differences in the rates of lon-
gitudinal changes in the LED among the groups after control-
ling for the same covariates. The effects of the PD subgroups on 
changes in the LED over time were tested using the time by PD 
subgroup interaction term. To investigate the hazard ratio (HR) 
of developing WO, LID, or conversion to dementia, we used a 
Cox proportional hazards model that included the same covari-
ates. We further adjusted for the total UPDRS-III score and cog-
nitive status in the Cox proportional hazards model for conver-
sion to dementia according to olfactory dysfunction. Data were 
analyzed using SPSS software, ver. 23 (IBM Corp., Armonk, NY, 
USA). p-values less than 0.05 were considered significant.
136
J Mov Disord  2020;13(2):133-141
JMD
RESULTS
Demographic and clinical characteristics of the study 
participants
According to the baseline CCSIT scores, 19.3% of PD patients 
had normal olfactory function, 59.6% had mildly decreased ol-
faction, and 21.1% had severe olfactory loss at the time of PD 
diagnosis (Table 1). Anosmic PD patients were older at PD on-
set, and a higher proportion of these patients were male com-
pared to the normosmic and hyposmic PD groups. The inter-
val from PD onset to CCSIT evaluation, follow-up duration, 
total disease duration, and proportion of RBD were not differ-
ent among the groups.
Baseline motor profiles of the study participants
The baseline parkinsonian motor score and DAT activity in 
the putamen were not different among the PD groups after con-
trolling for age, sex, and the interval from PD onset to CCSIT 
evaluation (Table 2). There was also no difference in the propor-
tion of clinical subtypes among the PD groups.
Baseline cognitive profiles of the study participants
At the baseline neuropsychological evaluation, the anosmic 
PD group had a higher proportion of MCI than the normosmic 
PD group (Table 2). There was no difference in the proportion 
of patients with amnestic MCI among the PD groups. Among 
the neuropsychological battery of tests, the anosmic PD patients 
showed significantly poorer performance on the K-BNT (p = 
0.005) and Stroop color reading (p = 0.023) items when uncor-
rected. Additionally, we investigated the association between 
olfactory function and neuropsychological performance using 
the CCSIT as a continuous variable. The CCSIT score was sig-
nificantly correlated with the K-BNT, Stroop color reading, and 
SVLT recognition scores after applying the FDR method (Sup-
plementary Table 1 in the online-only Data Supplement). The 
three PD groups showed no differences in any of the other neu-
ropsychological tests or in the DAT activity in the caudate. 
Longitudinal changes in the LED and occurrence of 
motor complications
A linear mixed model analysis showed that there were no 
differences in the rate of LED changes during the first three years 
of follow-up among the PD groups (time by PD subgroup inter-
action, p = 0.144) (Figure 1). A Cox proportional hazard model 
according to olfactory dysfunction in PD patients showed no 
difference in the occurrence of WO (Figure 2A) and LID (Fig-
ure 2B) among the PD groups.
Occurrence of PD dementia
The anosmic PD group showed a significantly higher con-
version rate to dementia than the normosmic [HR 3.89, 95% 
confidence interval (CI) 1.06–14.21] and hyposmic (HR 2.20, 
95% CI 1.04–4.66) PD groups, independent of age, sex, and in-
terval from PD onset to CCSIT evaluation (Figure 2C, Table 3). 
When we further adjusted for the total UPDRS-III score and 
cognitive status, the anosmic group still had a higher conversion 
rate to dementia than the normosmic (HR 3.99, 95% CI 1.08–
14.72) and hyposmic (HR 2.48, CI 1.15–5.32) PD groups. Ad-
ditionally, we investigated the HR of olfactory dysfunction for 
dementia conversion using the CCSIT as a continuous variable. 
The HR of the baseline CCSIT score for the risk of future de-
velopment of dementia was 0.73 (95% CI 0.61–0.87) after con-
trolling for age, sex, interval from PD onset to CCSIT evalua-
tion, total UPDRS-III score, and cognitive status.
DISCUSSION
The present study investigated the association of baseline ol-
factory function with motor and cognitive deficits and the lon-
gitudinal motor and cognitive outcomes in PD. The major find-
ings were as follows: 1) 81.1% of PD patients had decreased 
olfaction at the time of diagnosis, and 26.1% of PD patients had 
severe loss of olfaction; 2) olfactory dysfunction was not associ-
ated with initial parkinsonian motor symptoms but was associ-
ated with baseline dysfunction in the K-BNT and Stroop color 
Table 1. Baseline demographic and clinical characteristics of the study participants
Variables Normosmic PD Hyposmic PD Anosmic PD p value
Number (%) 44 (19.3) 136 (59.6) 48 (21.1) < 0.001
Age at onset, y 62.7 ± 8.4 64.9 ± 7.8 69.7 ± 6.8 0.067*†
Male, n (%) 19 (43.2) 53 (39.0) 32 (66.7) 0.004*†
PD onset to CCSIT evaluation, y 1.3 ± 1.3 1.5 ± 1.4 1.6 ± 1.5 0.530
Follow-up duration, y 5.9 ± 1.7 5.9 ± 1.8 5.8 ± 1.9 0.890
Total disease duration, y 7.3 ± 1.8 7.4 ± 2.1 7.3 ± 2.3 0.913
RBD, n (%) 11 (25.0) 57 (41.7) 17 (35.4) 0.125
Data are expressed as the mean ± standard deviation or number (percentage). *significant difference in the comparison between the normosmic 
and anosmic PD groups, †significant difference in the comparison between the hyposmic and anosmic PD groups. CCSIT: Cross-Cultural Smell Iden-
tification Test, PD: Parkinson’s disease, RBD: rapid eye movement sleep behavioral disorder.
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reading test, which reflect deficits in frontal and temporal func-
tions; 3) baseline olfactory dysfunction was neither associated 
with motor progression nor with the occurrence of motor com-
plications; and 4) baseline olfactory dysfunction predicted the 
progression to dementia regardless of baseline motor deficits 
and cognitive status. Taken together, these results suggest that, 
while baseline olfactory dysfunction is not associated with mo-
tor deficits and complications, it is associated with cognitive dys-
function and prognosis.
Severely decreased olfaction at the time of PD diagnosis was 
associated with MCI and poor performance in the K-BNT and 
Stroop color reading test. Previous studies reported that PD pa-
tients with MCI have worse olfactory function than those with 
intact cognition.9,19,20 This suggests the early involvement of the 
cortical Lewy body, a pathological hallmark of PD, in cases where 
there is initiation of neuropathological spread of the neurode-
Table 2. Baseline motor and cognitive profiles of the study participants
Variables Normosmic PD Hyposmic PD Anosmic PD p value
Motor profile
UPDRS motor score 20.7 (1.46) 22.85 (0.82) 24.06 (1.42) 0.253
Clinical subtype, n (%) 0.637
Tremor dominant 7 (15.9) 14 (10.3) 4 (8.3)
Akineto-rigid 19 (43.2) 51 (27.5) 20 (41.7)
Mixed 18 (40.9) 71 (52.2) 24 (50.0)
DAT activity in posterior putamen 1.33 (0.08) 1.41 (0.04) 1.37 (0.08) 0.634
Cognitive profile
Cognitive status, n (%)
Intact cognition/MCI 35 (79.5)/9 (20.5) 93 (68.4)/43 (31.6) 26 (54.2)/22 (45.8) 0.033*
Amnestic/nonamnestic 6 (66.7)/3 (33.3) 29 (67.4)/14 (32.6) 16 (72.7)/6 (27.3) 0.898
Neuropsychological performance
Digit span forward 0.17 (0.15) 0.41 (0.09) 0.19 (0.15) 0.231
Digit span backward -0.32 (0.16) -0.15 (0.09) -0.23 (0.16) 0.645
K-BNT -0.02 (0.15) -0.23 (0.09) -0.72 (0.15) 0.005*†
RCFT copy -0.10 (0.11) -0.32 (0.19) -0.52 (0.19) 0.088
SVLT immediate recall -0.03 (0.16) -0.17 (0.09) -0.44 (0.15) 0.169
SVLT delayed recall -0.34 (0.16) -0.44 (0.09) -0.52 (0.16) 0.734
SVLT recognition 0.08 (0.15) -0.09 (0.08) -0.40 (0.15) 0.079
RCFT immediate recall -0.36 (0.16) -0.16 (0.09) -0.53 (0.16) 0.106
RCFT delayed recall -0.19 (0.16) -0.14 (0.09) -0.43 (0.15) 0.260
RCFT recognition -0.06 (0.16) -0.03 (0.09) -0.25 (0.15) 0.301
COWAT semantic -0.08 (0.13) -0.23 (0.07) -0.36 (0.13) 0.337
COWAT phonemic -0.33 (0.17) -0.13 (0.10) -0.51 (0.17) 0.140
Stroop color reading -0.12 (0.18) -0.17 (0.10) -0.73 (0.18) 0.023*†
Total K-MMSE score 27.33 (0.33) 27.18 (0.19) 26.72 (0.32) 0.397
CDR-SOB 0.75 (0.11) 0.82 (0.06) 1.04 (0.11) 0.167
Data are expressed as an estimated mean (standard error) or number (percentage). *significant difference in the comparison between the normos-
mic and anosmic PD groups, †significant difference in the comparison between the hyposmic and anosmic PD groups. COWAT: Controlled Oral 
Word Association Test, CDR-SOB: Clinical Dementia Rating Sum of Boxes, DAT: dopamine transporter, K-BNT: Korean version of the Boston Nam-
ing Test, K-MMSE: Korean version of the Mini-Mental State Examination, MCI: mild cognitive impairment, PD: Parkinson’s disease, RCFT: Rey-Os-
terrieth Complex Figure Test, SVLT: Seoul Verbal Learning Test, UPDRS: Unified Parkinson’s Disease Rating Scale.

























Figure 1. Longitudinal changes in the levodopa-equivalent dose 
with time among the Parkinson’s disease (PD) groups according to 
olfactory function. There was no significant interaction between PD 
groups and time in the linear mixed model (p = 0.144).
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generative process through an olfactory route.21 However, het-
erogeneous results have been reported regarding which specific 
cognitive domain is impaired in association with olfactory dys-
function in PD: attentional deficit,10 visuospatial dysfunction,19 
memory impairment,22-24 or executive dysfunction.22,24 This can 
be attributed to the different ways of evaluating olfactory and 
cognitive functions and to studies that enrolled PD patients with 
various disease stages. Since antiparkinsonian drugs have the 
potential to influence a range of cognitive functions, it is neces-
sary to investigate the association between olfactory and cogni-
tive functions in early and drug-naïve PD patients. Furthermore, 
as we enrolled PD patients with a mean disease duration of less 
than 2 years at baseline evaluation, we can infer that, from the 
early stage of PD, olfactory deficits are closely related to specific 
cognitive dysfunction, and they are predictive of future develop-
ment of dementia. Imaging studies have revealed that olfactory 
dysfunction is associated with olfaction-related cortical atrophy, 
including piriform and orbitofrontal cortices25 or white matter 
disintegrity near the orbitofrontal cortex in PD.20 Since olfaction-
related structures are located near and within the basal and me-
dial frontal regions and the inferior and medial temporal areas, 
Lewy body entry through the nasal route could primarily affect 
these regions from the early stage of PD.21 The suggested neural 
correlate involved in naming is the inferior temporal cortex26 
and that of the Stroop color reading test is the prefrontal cortex.27 
From our results, we can infer that baseline olfactory dysfunc-
tion is closely linked to the early presence of Lewy bodies in the 
frontotemporal regions, which leads to dysfunction in naming 
and frontal execution in PD. Pathological studies are necessary 
to investigate the timing and preferential site for cortical involve-
ment of Lewy bodies according to olfactory dysfunction.
We found that PD patients with severe olfactory dysfunction 
at the time of PD diagnosis had a higher rate of conversion to 
dementia than other PD patients, independent of age, sex, and 
baseline motor and cognitive functions. Consistent with our 
study, previous studies have reported that baseline hyposmia 
in PD patients is an independent risk factor for the subsequent 
development of MCI6 and dementia.3 Additionally, PD patients 
with baseline hyposmia had a characteristic cerebral metabolic 
decline that was identical to that in PD dementia.8 Olfactory dys-
function was also closely associated with cognitive decline, even 
in dementia-free subjects28 and in patients with amnestic MCI 
Table 3. Cox proportional HR for conversion to dementia among the study participants
Univariate Multivariate* Multivariate†
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Group according to CCSIT score
Normosmic group Reference Reference Reference
Hyposmic group 1.96 (0.58–6.70) 0.282 1.77 (0.51–6.08) 0.366 1.61 (0.46–5.61) 0.455
Anosmic group 5.79 (1.69–19.90) 0.005 3.89 (1.06–14.21) 0.040 3.99 (1.08–14.72) 0.038
CCSIT as continuous variable 0.71 (0.61–0.83) < 0.001 0.73 (0.61–0.86) < 0.001 0.73 (0.61–0.87) < 0.001
*adjusted for age, sex, and interval between PD onset and CCSIT evaluation, †adjusted for age, sex, interval between PD onset and CCSIT evalua-
tion, total Unified Parkinson’s Disease Rating Scale-III score, and cognitive status. CCSIT: Cross-Cultural Smell Identification Test, CI: confidence in-
terval, HR: hazard ratio, PD: Parkinson’s desease.












































































































































Figure 2. Estimated survival function for the Cox regression of time to (A) the onset of WO, (B) the onset of LID, and (C) the conversion to 
dementia among the PD groups according to olfactory function. *a significant difference between the PD groups. LID: levodopa-induced 
dyskinesia, PD: Parkinson’s disease, WO: wearing-off.
A B C
No. at risk: No. at risk: No. at risk:
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and Alzheimer’s disease (AD).29 Worse olfaction may reflect ear-
ly and severe extranigral Lewy body pathology in the cortical ar-
eas, which could accelerate the progression of cognitive decline 
and conversion to dementia.6 Early damage to the forebrain cho-
linergic system could be another explanation for the association 
between olfactory dysfunction and cognitive decline. Patients 
with PD show substantial neuronal loss in the nucleus basalis 
of Meynert.30 Odor identification test scores have been shown 
to be positively correlated with acetylcholinesterase activity in 
the limbic area.23 PET studies have revealed widespread and 
profound cholinergic dysfunction in PD dementia.31 If we can 
identify a temporal relationship between olfactory impairment 
and cholinergic dysfunction, it will enable us to elucidate the role 
of olfactory dysfunction in cognitive decline. Last, co-accumu-
lation of AD neuropathologies such as amyloid plaque and neu-
rofibrillary tangles can link olfactory dysfunction and cognitive 
decline. Tau-related pathology has been found in the anterior ol-
factory nucleus in PD.32 Olfactory impairment has been shown 
to be associated with atrophy in AD signature areas in demen-
tia-free older adults.33 Concomitant AD neuropathologies have 
been found to be associated with rapid cognitive decline in Lewy 
body disorders.34 Since patients in the anosmic PD group in this 
study had a higher age of onset and proportion of MCI than the 
other groups, AD co-pathology may have accelerated cognitive 
decline and dementia conversion in the anosmic PD group. It 
is necessary to investigate the burden of amyloid-β burden ac-
cording to the baseline olfactory function in PD.
Olfactory dysfunction was not associated with baseline par-
kinsonian motor severity, putaminal DAT activity, the longitu-
dinal LED increment, or long-term motor complications. A 
previous study reported that PD patients stratified by olfactory 
tertile had similar baseline UPDRS motor scores and changes 
in UPDRS scores.6 The absence of an effect of levodopa use on 
olfactory performance is additional indirect evidence of no re-
lationship between dopamine and olfaction.35 Studies using DAT 
imaging showed no association between putaminal DAT activ-
ity and olfactory function.11 Two studies have reported contra-
dictory results, suggesting that olfactory dysfunction is corre-
lated with higher motor severity and LED, freezing of gait, and 
putaminal DAT binding.7,36 However, these studies enrolled PD 
patients with a wide range of disease durations and did not ad-
just for the disease duration, which was closely related to motor 
severity. It would be difficult to investigate the independent rela-
tionship between olfactory function and motor function without 
controlling for this factor. These results suggest that PD patients 
have similar nigral pathologic burdens regardless of olfactory 
dysfunction. In terms of motor complications such as WO and 
LID, low putaminal DAT activity,37 disease severity,38 and a high 
dose of levodopa39 are risk factors for WO and LID, none of 
which were associated with baseline olfactory dysfunction in 
this study. Fullard et al.6 also found that olfactory dysfunction 
was not associated with putaminal DAT activity, UPDRS motor 
score, or disease progression. Therefore, we can infer that early 
and severe olfactory dysfunction and possible extranigral pa-
thology are unlikely to be associated with presynaptic nigros-
triatal degeneration and long-term synaptic plasticity.40 
This study has several limitations. First, we evaluated olfacto-
ry function only based on the aspect of identification, which is 
thought to require cognitive memory processing,41 even though 
olfaction can be assessed using various methods, including odor 
discrimination and detection threshold tasks. Second, we did 
not monitor UPDRS motor scores regularly, and we did not per-
form regular neuropsychological tests. Instead, we calculated 
the LED increment, which has not been validated as a marker 
reflective of motor progression and monitored the occurrence 
of motor and cognitive complications. Investigating the associa-
tion between olfactory dysfunction and the progression of mo-
tor and cognitive function is important for the elucidation of the 
role of olfactory impairment and the pathological spread of ni-
gral and extranigral pathologies in PD. Third, we did not con-
firm the associations between the nigral and extranigral burden 
of PD pathology and olfactory dysfunction. Although we used 
cortical Lewy body involvement to propose a relationship be-
tween olfactory and cognitive dysfunction, other possible mech-
anisms, such as cholinergic dysfunction or concomitant Alzheim-
er’s disease pathology, could also be associated. Future studies 
are necessary to investigate these factors to identify the role of 
olfaction in cognitive decline in PD. Last, this is a retrospective 
cohort study, which has some disadvantages; the lack of unifor-
mity in baseline evaluations and differential losses to follow-up 
in some patients may have introduced bias, and the collection of 
data at different intervals prevented us from identifying an ex-
posed cohort and comparison group appropriately. A prospec-
tive study is necessary to clearly identify whether olfactory def-
icits are an independent risk factor for cognitive complications. 
Despite these limitations, in this study, we used a large sample 
of PD patients and investigated motor and cognitive dysfunc-
tion in the aspects of baseline function, long-term outcomes, 
and DAT activity in the same cohort. This resulted in reliable 
and generalizable results with statistical consistency.
We demonstrated that baseline olfactory dysfunction was not 
associated with motor deficits and complications, but it was as-
sociated with cognitive dysfunction and dementia conversion. 
This suggests that early and severe olfactory impairment is like-
ly to be associated with early cortical involvement, probably in 
the frontotemporal region, and the rapid spreading of Lewy body 
pathology. Olfactory dysfunction can be a useful biomarker when 
assessing patients with PD who are at risk of early development 
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of cognitive dysfunction and dementia.
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